Arguably the most well-known SERD is AstraZeneca’s Faslodex, which was approved in 2002 for breast cancer and is administered ...

Imlifidase, an IgG-destroying enzyme, could receive FDA approval in the second half of 2026 and hit peak sales of $306 ...

Truist analysts called the results "encouraging" while pointing out certain unknowns in the data. Immuneering plans to kick ...

Ladenburg, Germany–based Heidelberg Pharma is laying off approximately 75% of its workforce in a bid to extend its cash ...

Though details remain scant, the pending order is expected to be the latest effort in President Donald Trump's campaign to ...

Companies that have broken ground on or are actively constructing manufacturing facilities in the U.S. are exempted from the ...

Three draft recommendation documents published on Wednesday are intended to guide drug sponsors and accelerate the ...

The regulatory greenlight was backed by two Phase III trials that showed normalized growth hormone levels in patients with ...

While Harmony management has not disclosed future plans for ZYN002, Jefferies analysts expect the asset to be shelved.

The agency also pointed to the use of Tylenol and other acetaminophen products during pregnancy as being potentially linked ...

The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials ...

Talent acquisition leaders at leading pharma and biotech organizations are leveraging technologies, including automation, to ...